A New Therapy for Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia (CAH) is a rare inherited endocrine disorder caused by genetic mutations in enzymes required for the synthesis of cortisol. It is characterized by growth of the adrenal glands, adrenal insufficiency, mineralocorticoid deficiency, and androgen excess.

Despite glucocorticoid replacement, most patients are unable to achieve hormonal balance. Spruce’s lead drug candidate, SPR001, is intended to correct hormone imbalance by reducing the overdrive on the adrenal gland.

Learn About CAH + View Our Research Pipeline +

Enrolling Now

Congenital Adrenal Hyperplasia Clinical Trials 2017

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new, once-a-day therapy for CAH. Visit www.CAHclinicaltrial.com to see if you pre-qualify.

Learn More